Sensorineural Hearing Loss

2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Rinri Therapeutics
Rinri TherapeuticsUK - Sheffield
1 program
1
Otic neural progenitorsPhase 1/21 trial
Active Trials
NCT07032038Not Yet RecruitingEst. Jul 2027
Contineum Therapeutics
1 program
1
PIPE-505Phase 1/21 trial
Active Trials
NCT04462198Completed28Est. Jun 2021
Oticon
OticonDenmark - Smørum
1 program
PupillometryN/A1 trial
Active Trials
NCT03212924CompletedEst. Mar 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Rinri TherapeuticsOtic neural progenitors
Contineum TherapeuticsPIPE-505
OticonPupillometry

Clinical Trials (3)

Total enrollment: 28 patients across 3 trials

NCT07032038Rinri TherapeuticsOtic neural progenitors

First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant

Start: Oct 2025Est. completion: Jul 2027
Phase 1/2Not Yet Recruiting
NCT04462198Contineum TherapeuticsPIPE-505

Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss

Start: Oct 2020Est. completion: Jun 202128 patients
Phase 1/2Completed
NCT03212924OticonPupillometry

Listening Effort in Cochlear Implant Users

Start: Sep 2017Est. completion: Mar 2018
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space